OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 43.6% in January

OnKure Therapeutics, Inc. (NASDAQ:OKUR) saw a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 14,187 shares, an increase of 43.6% from the January 15th total of 9,877 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 68,471 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 68,471 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd. Wall Street Zen upgraded OnKure Therapeutics to a “sell” rating in a research report on Saturday, November 1st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $32.00.

Hedge Funds Weigh In On OnKure Therapeutics

Large investors have recently bought and sold shares of the stock. Acorn Capital Advisors LLC increased its stake in shares of OnKure Therapeutics by 97.2% in the second quarter. Acorn Capital Advisors LLC now owns 2,839,674 shares of the company’s stock worth $6,787,000 after buying an additional 1,400,000 shares during the period. Shay Capital LLC raised its stake in shares of OnKure Therapeutics by 17.4% during the third quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock valued at $2,524,000 after acquiring an additional 135,888 shares during the last quarter. Prosight Management LP boosted its holdings in shares of OnKure Therapeutics by 204.9% during the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after purchasing an additional 548,950 shares during the period. Rosalind Advisors Inc. purchased a new stake in shares of OnKure Therapeutics during the fourth quarter worth about $2,118,000. Finally, Highbridge Capital Management LLC grew its stake in shares of OnKure Therapeutics by 51.2% in the second quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock worth $1,586,000 after purchasing an additional 224,810 shares during the last quarter. 90.98% of the stock is owned by hedge funds and other institutional investors.

OnKure Therapeutics Stock Up 0.4%

Shares of NASDAQ:OKUR opened at $2.42 on Tuesday. The stock has a market cap of $32.79 million, a PE ratio of -0.51 and a beta of 0.46. The company’s fifty day moving average is $2.85 and its 200 day moving average is $2.80. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $6.18.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.